Laboratorios Farmaceuticos Rovi, S.A. is a fully-integrated Spanish pharmaceutical company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. Headquartered in Madrid, the company operates a dual-pillar business model comprising a proprietary specialty pharmaceutical division and a Contract Development and Manufacturing Organization (CDMO) division. The specialty pharmaceutical segment, which accounts for the majority of its revenue, features a strong low-molecular-weight heparin (LMWH) franchise, including its flagship product Bemiparin, as well as Okedi, a prolonged-release schizophrenia treatment based on its proprietary ISM technology. The CDMO division provides high-value toll manufacturing services, notably specializing in pre-filled syringes, vials, and solid oral forms, and gained global prominence for manufacturing Moderna's mRNA COVID-19 vaccine. Rovi maintains a direct commercial presence in key European markets and distributes its products globally through strategic partnerships.
